Daiichi SankyoㆍSanten below 3% of growth
Eisai, grew 34.97% with Lenvima
Japanese pharmaceutical companies had been sluggish in the outpatient prescription market last year.
According to UBIST, the combined amount of over-the-counter sales for nine Japanese pharmaceutical companies in 2020 was KRW 675.2 billion, down 1.56% from 2019.
In particular, large companies showed poor performance. Astellas, the only Japanese pharmaceutical company with KRW 200 billion in prescription, showed a 7.29% contraction and hardly kept the KRW 200 billion mark.
Takeda’s prescription decreased 4.64% from KRW 135.7 billion to KRW 129.4 billion, while Otsuka also declined 2.05% from KRW 72.2 billion to KRW 70.7 billion, and Kyowa Kirin Korea fell from KRW 4.9 billion to KRW 4.2 billion.
Daiichi Sankyo, the second-largest Japanese pharmaceutical company after Astellas, got off from degrowth but grew only 2.84% YoY.
Santen’s annual prescription also rose from KRW 70 billion to KRW 80 billion, but the growth did not exceed 3%.
On the other hand, despite the difficulty of decreasing prescription performance of three drugs listed on the UBIST by more than 10%, Eisai increased by nearly 35% with its first-line therapy for liver cancer Lenvima, from KRW 4.3 billion to KRW 10 billion.
Mitsubishi Tanabe Pharma, which only has Diquas-S on the list, rose to KRW 10 billion mark with double-digit growth, and Kowa, with Kalimet, expanded from KRW 100m million to KRW 400million.
